文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

伊匹木单抗联合纳武利尤单抗对比纳武利尤单抗单药治疗黑色素瘤脑转移患者(ABC):一项多中心、开放标签、随机2期研究的7年随访

Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
PubMed 文献 · Lancet Oncol · 2025-02-17

该开放标签随机2期研究在澳大利亚4个中心纳入79例免疫治疗初治的活跃黑色素瘤脑转移患者,随机分配至伊匹木单抗联合纳武利尤单抗组(A组)或纳武利尤单抗单药组(B组),中位随访7.6年。A组颅内客观缓解率为51%,7年颅内无进展生存率42%,7年总生存率48%,均高于B组。作者认为伊匹木单抗联合纳武利尤单抗应作为黑色素瘤脑转移的标准治疗。

要点

  • A组颅内客观缓解率51%,B组20%,C组6%。
  • A组7年颅内无进展生存率42%,B组15%,C组6%。
  • A组7年总生存率48%,B组26%,C组13%。

核心结论

  • 作者认为,伊匹木单抗联合纳武利尤单抗在活跃无症状脑转移患者中至少维持疗效至7年。
  • 作者建议, upfront 伊匹木单抗联合纳武利尤单抗应作为黑色素瘤脑转移患者的标准治疗。
  • 作者指出,一项探讨立体定向手术在这一新范式中作用的试验正在进行中。

研究设计与样本

  • 开放标签、随机、2期研究,在澳大利亚4个中心(2个研究所癌症中心和2个大学教学医院)开展。
  • 纳入年龄≥18岁、活跃、免疫治疗初治的黑色素瘤脑转移且ECOG体能状态0-2的患者。
  • 无症状且既往未接受脑部定向治疗的患者按5:4随机分配至A组(伊匹木单抗3 mg/kg联合纳武利尤单抗1 mg/kg每3周4次,随后纳武利尤单抗3 mg/kg每2周)或B组(纳武利尤单抗3 mg/kg每2周);既往接受脑部定向治疗、有神经系统症状或软脑膜疾病的患者分配至C组(非随机,纳武利尤单抗3 mg/kg每2周)。
  • 2014年11月4日至2017年4月21日,评估89例患者,入组79例,分配至A组(n=36)、B组(n=27)或C组(n=16);3例因不符合条件被排除(A组1例,B组2例)。
  • 76例患者中,女性17例(22%),男性59例(78%);数据截止日期为2024年3月26日,中位随访7.6年(IQR 6.9-8.2)。

主要发现

  • 颅内客观缓解:A组18例(51% [95% CI 34-69]),B组5例(20% [7-41]),C组1例(6% [0-30])。
  • 7年颅内无进展生存率:A组42%(95% CI 29-63),B组15%(6-39),C组6%(1-42)。
  • 7年总生存率:A组48%(34-68),B组26%(13-51),C组13%(3-46)。
  • 安全性结果与主要分析一致。
  • 死亡50例,其中A组18例(51%),B组18例(72%),C组14例(88%)。

临床怎么用

  • 作者建议,初治伊匹木单抗联合纳武利尤单抗应作为黑色素瘤脑转移患者的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with melanoma brain metastases respond well to immunotherapy, but long-term comparative survival data are scarce. We aimed to assess the efficacy of ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases at 7 years. METHODS: This open-label, randomised, phase 2 study was conducted at four sites (two research institute cancer centres and two university teaching hospitals) in Australia. Patients aged 18 years or older with active, immunotherapy-naive melanoma brain metastases and Eastern Cooperative Oncology Group performance status of 0-2 were eligible. Asymptomatic patients with no previous brain-directed therapy were randomly assigned (5:4) using the biased-coin minimisation method (after a safety run-in of six patients) to cohort A (intravenous ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for four doses, then nivolumab 3 mg/kg every 2 weeks) or cohort B (intravenous nivolumab 3 mg/kg every 2 weeks). Patients with previous brain-directed therapy, neurological symptoms, or leptomeningeal disease were assigned to cohort C (non-randomised; intravenous nivolumab 3 mg/kg every 2 weeks). The primary endpoint was best intracranial response (complete or partial response) from week 12. Secondary survival endpoints included intracranial progression-free survival and overall survival. Safety was assessed from the first dose of treatment to at least 100 days after treatment discontinuation. Analyses were performed in patients who received at least one dose of study drug. The main analysis has been reported, and this is a long-term follow up of the ABC trial. This trial is registered with ClinicalTrials.gov, NCT02374242, and is ongoing. FINDINGS: Between Nov 4, 2014, and April 21, 2017, 89 patients were assessed for eligibility, 79 of whom were enrolled and assigned to cohort A (n=36), cohort B (n=27), or cohort C (n=16). Three patients (one in cohort A and two in cohort B) were excluded due to ineligibility. 17 (22%) of 76 patients were female and 59 (78%) were male. At data cutoff (March 26, 2024), the median follow-up was 7·6 years (IQR 6·9-8·2). Overall intracranial responses occurred in 18 (51% [95% CI 34-69]) patients from cohort A, five (20% [7-41]) from cohort B, and one (6% [0-30]) from cohort C. 7-year intracranial progression-free survival was 42% (95% CI 29-63) in cohort A, 15% (6-39) in cohort B, and 6% (1-42) in cohort C. 7-year overall survival was 48% (34-68) in cohort A, 26% (13-51) in cohort B, and 13% (3-46) in cohort C. Safety results were consistent with the primary analysis. 50 patients died, including 18 (51%) from cohort A, 18 (72%) from cohort B, and 14 (88%) from cohort C. INTERPRETATION: Our findings suggest that ipilimumab plus nivolumab maintains efficacy to at least 7 years in patients with active asymptomatic brain metastasis. Upfront ipilimumab plus nivolumab should be the standard of care for patients with melanoma brain metastasis; a trial investigating the role of stereotactic surgery in this new paradigm is ongoing. FUNDING: Melanoma Institute Australia and Bristol Myers Squibb.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Long GV, Atkinson V, Lo SN, et al. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2025. PMID: 39978375. doi:10.1016/S1470-2045(24)00735-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。